Clearance in Primary Ciliary Dyskinesia

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of North Carolina, Chapel Hill

About this trial

Understanding mechanisms of mucus clearance from the airways may lead to treatments in muco-obstructive lung conditions. Mucociliary clearance (MCC) scans are a way to measure the rate at which a person's lungs can clear inhaled particles. Through a single-arm pilot study in participants with primary ciliary dyskinesia (PCD), the investigators will evaluate the effect of exercise as a way to increase clearance through a mechanism called gas liquid transport (GLT) where the faster flow of air through the lungs during exercise is able to clear more particles. The investigators will repeat MCC measures with exercise after administering hypertonic saline (HS) to evaluate the effects of mucus hydration on both GLT and cough clearance (CC).

Aim 1. To quantify non-ciliary, non-cough mechanisms of mucus clearance (i.e., GLT) in PCD through an MCC protocol that introduces a standardized exercise intervention after isotope delivery.

Aim 2. To evaluate whether exercise-induced GLT and/or CC are responsive to hydrator intervention, using a short acting bronchodilator with 7% HS prior to isotope delivery followed by MCC with exercise intervention.

Eligibility criteria

Qualifiers

18 years old or older

Diagnosis of PCD with supporting genetics

Lung function with forced expiratory volume in 1 second (FEV1) percent predicted >30%

Ability to exercise for 20 minutes (Exercise Assessment performed at screening visit)

Disqualifiers

Intolerance to 7% HS

Failure of HS tolerance test (HSTT) at visit 1 (V1), defined as a decline of 10% in FEV1 from baseline pre-bronchodilator (BD) FEV1 after 7% HS

Intolerance to levalbuterol

Exercise-induced asthma

Trial design

Treatments tested in this trial

  • Exercise
  • HS pretreatment with Exercise

Treatment groups

8 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of North Carolina, Chapel Hill

Lead sponsor

Cystic Fibrosis Foundation

Collaborator